GLP-1: Glucagon-like peptide-1 ... Published and preliminary data have shown once-weekly exenatide to result in greater A1c reduction than exenatide twice daily; and as a second- or third-line ...
The relative reduction in major adverse cardiovascular events (MACE) with SGLT2 inhibitors was greater in older versus younger participants, but the relative reduction in MACE with GLP-1 receptor ...
The once- and twice-daily GLP-1 RAs are now well established for ... has been shown in most studies to result in a greater reduction of A1c and FPG. While it has not been compared head-to-head ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback